How do you want your Altace be delivered? Choose here!

BRISTOL, Tenn. — King Pharmaceuticals, Inc. (NYSE:KG) announced today that total revenues increased 7% to $516 million during the first quarter ended March 31, 2007, compared to $484 million in the first quarter of 2006. Reported net income equaled $116 million and diluted income per share equaled $0.48 during the first quarter of 2007, compared to net earnings of $51 million and diluted earnings per share o…

Sept. 15, 2006 — A widely prescribed drug used to treat type 2 diabetes is
also highly effective for preventing the disease, researchers reported today at
a meeting in Copenhagen, Denmark.
People at high risk for diabetes who took the drug Avandia reduced their
risk of developing the disease by 60% in the three-year trial conducted in 21
countr…

Up to 8 percent of men older than 50 years develop aortic aneurysms. Without treatment, approximately one third of aneurysms rupture, and one half of these patients die before admission to the hospital. The total mortality rate after rupture is 80 to 90 percent. The mortality rate of elective repair of aneurysms before rupture is approximately 5 percent, and the overall complication rate is around 32 percent. The risk of developing aortic aneurysm or other cardiovascular abnormalities has be…

COLUMBUS, Ohio, June 18 /PRNewswire/ — Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Ramipril Capsules, 1.25mg, 2.5mg, 5mg and 10mg by the U.S. Food and Drug Administration. The 1.25mg, 2.5mg, 5mg and 10mg strengths will be available in various packaging configurations. Roxane Laboratories Rami…

May 18, 2000 (New York) — Type 2 diabetes and high blood pressure go
together like ham and eggs, but are even more lethal to the heart.
Type 2 diabetes, also called non-insulin dependent diabetes or adult-onset
diabetes, is most often seen in persons who are overweight. The disease usually
appears in middle age, but recently there has been an increase in cases of type
2 diabetes among adole…

M2 PRESSWIRE-11 May 2007-Biotech News: BWR Begins Tracking King Pharmaceuticals, Inc.(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:11052007 King Pharmaceuticals rules! The company makes branded pharmaceuticals, including cardiovascular, critical care, and neuroscience products. Among the company’s…

BALTIMORE, June 11 /PRNewswire/ — Lupin Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company’s Abbreviated New Drug Application (ANDA) for Ramipril capsules, 1.25 mg. 2.5 mg, 5 mg and 10 mg. Commercial shipments of the product have commenced.
Lupin’s Ramipril capsules are the AB-rated generic equivalent of King Pharmaceutical’s Altace(R) capsules, indicated for the treatment of hypertension. The brand produ…

BRISTOL, Tenn. — King Pharmaceuticals, Inc. (NYSE:KG) announced today that total revenues increased 8% to $500 million during the second quarter ended June 30, 2006, compared to $463 million in the second quarter of 2005. Including special items, net earnings increased to $111 million and diluted earnings per share increased to $0.46 during the second…

Oct. 16, 2001 — A popular drug used to treat high blood pressure and heart disease, and recently shown to help prevent strokes and heart attacks, also appears to reduce the risk of developing diabetes. In a large trial first reported last year, researchers found that people at high risk for developing diabetes who ta…

BRISTOL, Tenn. — King Pharmaceuticals, Inc. (NYSE:KG) announced today that the Company has positive top-line results from the Phase III clinical trial evaluating the efficacy and safety of the Company’s ALTACE([R]) (ramipril) diuretic fixed-dose combination product. The Company is continuing to evaluate the trial data and expects to present the findings in detai…